Related Experiment Video
Updated: Jun 3, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Patent reform in the United States
1Center for Biomedical Ethics and Humanities, Program in Ethics and Policy in Healthcare Systems, University of Virginia, Charlottesville, VA 22901, USA. AMH2R@hscmail.mcc.virginia.edu
Abstract:
The recent financial meltdown has muted the patent reform debate in the United States. But given that President Obama, as well as many members of Congress, support patent reform, we expect the debate to resurface. In this essay, we look carefully at reports from three prestigious organizations which have been enormously influential in the debate. We examine the empirical basis contained in these reports upon which proposed legislative changes are based. We conclude that the empirical data being used to justify the need for reform either has serious methodological limitations or is non-existent. Moreover, we review recent court decisions which have already altered the patent environment calling into further question whether the limited data that exists is still applicable. The effect of these recent decisions has not been adequately evaluated or assessed. Thus, we recommend other empirical studies are needed to inform public policy as to whether patent reform is necessary.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Regulation
Drug Products: Biologics, Biosimilars and Interchangeables
Standards of Care I
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Drug Nomenclature

